摘要 |
The invention provides methods of identifying candidate psychiatric patients, or patients with movement disorder, for treatment with medication that acts at a D2 dopan-line receptor site or increases density of D2 dopamine receptors. The method comprises determining a patient's DRD2 genotype. Patients having the Taq1A (A1) allele (A1 + allelic status) are candidates for treatment with high dose, high binding antipsychotics and/or SSRIs that influence D2 receptor density. Patients lacking the Taq1A allele (A1- allelic status) are candidates for treatment with low dose, low binding atypical antipsychotics, and are not likely to respond well to these SSRIs. |
申请人 |
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;NOBLE, ERNEST, P.;YOUNG, ROSS, M.;LAWFORD, BRUCE, R.;STATE OF QUEENSLAND ACTING THROUGH QUEENSLAND HEALTH;THE UNIVERSITY OF QUEENSLAND |
发明人 |
NOBLE, ERNEST, P.;YOUNG, ROSS, M.;LAWFORD, BRUCE, R. |